A new deal with major drugmakers, unveiled by U.S. President Donald Trump on Thursday, aims to expand coverage and cut prices for popular weight-loss drugs south of the border.

The deal with Eli Lilly and Novo Nordisk is set to expand Medicare coverage of Zepbound and Wegovy, two GLP-1 receptor agonist medications . GLP-1 agonists — which include semaglutide medications such as Wegovy and Ozempic — are a class of medications that mimic the GLP-1 hormone to help treat diabetes and obesity. They work by stimulating insulin release, slowing stomach emptying and decreasing appetite.

In the U.S., access has remained limited because of spotty insurance coverage and high cost, which can be upward of $500 US a month for higher doses. So how much could Trump’s announcement really cut costs? And

See Full Page